Sandra A. Gardiner - 14 Dec 2021 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Reporting relationship: CFO & EVP Admin. and Finance
Issuer ticker: PLSE
Reported as of: 14 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Feb 2022, 12:42:12 UTC
Next SEC filing: 03 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact

Key filing fact

Sandra A. Gardiner filed Form 4 for Pulse Biosciences, Inc. (PLSE) on 28 Feb 2022.

Key facts

This page summarizes Sandra A. Gardiner's Form 4 filing for Pulse Biosciences, Inc. (PLSE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Feb 2022, 12:42.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLSE transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +25,961
Change %: +100%
Price: $0.000000
Shares after: 51,922
Date: 14 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,961
Exercise price: $13.94
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On November 18, 2019, the reporting person was granted an option to purchase 103,842 shares of the issuer's common stock. The option vests based upon the achievement of performance objectives, with vesting targets no less than 25% vesting per year upon achievement of said objectives established by the Compensation Committee of the issuer, subject to the reporting person's continued service through each vesting date. The performance objectives for 2021 were met, resulting in the vesting of the option as to 25,961 shares.

Footnote F2

Represents the options which vested on the 2020 vesting date and the options which vested on the 2021 vesting date.